Artiva Bio president Aslan sells $153k in ARTV stock

Aslan Fred, President and CEO of Artiva Biotherapeutics, Inc. (NASDAQ:ARTV), sold 25,500 shares of common stock on October 17, 2025, at a price of $6.0, totaling $153,000. The sale comes amid a significant 114% surge in share price over the past week, with InvestingPro data indicating the stock is currently trading in overbought territory.

According to a Form 4 filing with the Securities and Exchange Commission, the transaction was executed under a Rule 10b5-1 trading plan adopted on July 23, 2024. Following the sale, Aslan directly owns 356,721 shares of Artiva Biotherapeutics. The company maintains a strong balance sheet with more cash than debt, though InvestingPro analysis reveals rapid cash burn and indicates the stock is currently overvalued. Discover 10+ additional exclusive insights and detailed financial metrics with InvestingPro’s comprehensive research report.

In other recent news, Artiva Biotherapeutics has received Fast Track Designation from the U.S. Food and Drug Administration for its AlloNK therapy in combination with rituximab, targeting refractory rheumatoid arthritis. This development marks AlloNK as the first drug candidate in the deep B-cell depleting therapeutic category to achieve this status for refractory RA. The company has prioritized this condition as the lead indication for its AlloNK clinical development program. Alongside this regulatory milestone, Cantor Fitzgerald has reiterated its Overweight rating on Artiva Biotherapeutics, maintaining a price target of $10.00. The endorsement comes after Artiva’s announcement regarding its Allo-NK cell therapy program, where over 20 patients have been treated across approximately 12 centers. The program demonstrates a strong enrollment pace and acceptance of the lymphodepletion protocol in community settings. These recent developments reflect Artiva’s strategic focus on advancing its cell therapy candidate in autoimmune disorders.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.